Hims & Hers Adds Lilly GLP-1 Treatments To Lineup – CEO Compares It To Netflix’s Early Days

• Hims & Hers CEO Andrew Dudum noted that, like Netflix gave users the choice of what they wanted most, Hims & Hers is similarly offering GLP-1 treatments on its platform.
• The telehealth platform now has Eli Lilly’s Zepbound, Mounjaro, and Foundayo, in addition to Novo Nordisk’s Ozempic and Wegovy.
• Access to these medications requires an active membership, available for $39 for the first month and $149 thereafter.

Shares of Hims & Hers Health Inc. (HIMS) gained in Thursday’s opening trade after the company announced that it is expanding its lineup of GLP-1 treatments on the platform to include offerings from Eli Lilly & Co. (LLY).

Hims & Hers stated that Lilly’s Zepbound, Mounjaro, and Foundayo are now available to providers on the platform, allowing them to offer self-pay pricing for these treatments to their customers.

This comes a month after the company launched a waitlist for Novo Nordisk AS’s (NVO) Ozempic and Wegovy.

Hims & Hers shares were up nearly 4% in Thursday’s opening trade.

CEO Compares It To Netflix’s Early Days

Hims & Hers CEO Andrew Dudum compared the development with Netflix Inc.’s (NFLX) early days.

“In many ways, today reminds me of Netflix’s early days, when everyone talked about whether they would have the latest blockbuster in their catalog. As if Netflix’s success depended on its ability to become the distribution channel for a single film,” Dudum said in a post on X.

He added that people missed the forest for the trees, noting that Netflix was prioritizing choice and inventing new pathways to what people wanted most.

“By offering a full range of FDA-approved GLP-1s on our platform, we’re similarly giving our customers more choices through all the tools we have available – and we’ll continue to push here on behalf of everyone who depends on us for their care,” he said.

What Are The Weight Loss Options On Hims & Hers?

Hims & Hers currently offers a range of FDA-approved GLP-1 treatments on its platform.

This includes Zepbound, Zepbound Vial, and Zepbound KwikPen, with prices starting at $199 per month. The telehealth platform also offers the Foundayo pill at $149 per month and Mounjaro at $1,899 per month.

Customers can also opt for Novo Nordisk’s offerings, such as Ozempic and Wegovy, in pill or pen form, with prices starting at $149 per month.

Access to these medications requires an active membership, available for $39 for the first month and $149 thereafter.

The company previously stated that it would educate U.S. weight-loss customers about their options across a broader range of FDA-approved treatments. When providers determine it is clinically appropriate, Hims & Hers will help support a smooth transition to these medications, it said.

How Did Retail Traders React?

Retail sentiment on Stocktwits around Hims & Hers trended in the ‘extremely bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.

One bullish user stated that the HIMS stock could see a run-up before the next earnings report.

Another user referenced Dudum’s comparison with Netflix, saying that exciting times are ahead.

HIMS stock is down 8% year-to-date, but up 12% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 33% over the past 12 months, while the Vanguard Small-Cap Index Fund ETF Shares (VB) is up 35%.

NVO stock is down 24% YTD, while LLY stock is down 14%.

Also See: TXN Stock Extends Gains To 6th Consecutive Week — Why Are Analysts Bullish?

For updates and corrections, email newsroom[at]stocktwits[dot]com.